According to the agreement, Bayer will apply Chromobody technology for real time monitoring of cell cycle progression in drug discovery.
The Chromobody Technology, a patented, universal live cell imaging technology, allows to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells.
The Cell Cycle Chromobody cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a non-invasive manner while providing full flexibility to multiplex with other procedures.
ChromoTek R&D head Dr Kourosh Zolghadr said, "We are pleased to offer our customers efficient tools for achieving more detailed and physiologically relevant information on the effects of drug candidates on cell cycle progression."